We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
3 watching
Current Price
$34.16
$-1.87
(-5.19%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
939.32M
52-Week High
40.43
52-Week Low
7.09
Average Volume
0.17M
Dividend Yield
--
P/E Ratio
--
Market Capitalization939.32M
52-Week High40.43
52-Week Low7.09
Average Volume0.17M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
1month ago
Nuvalent Announces Closing of Upsized Public Offering of Common Stock Nuvalent Announces Closing of Upsized Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 3, 2022 CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical...
PR Newswire
1month ago
Nuvalent Announces Pricing of Public Offering of Common Stock Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Oct. 31, 2022 CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused...
PR Newswire
1month ago
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients...
PR Newswire
1month ago
Thinking about buying stock in Nuvalent, Tesla, Flagstar Bancorp, Mullen Automotive, or GameStop? Thinking about buying stock in Nuvalent, Tesla, Flagstar Bancorp, Mullen Automotive, or GameStop? PR Newswire NEW YORK, Oct. 28, 2022 NEW YORK, Oct. 28, 2022 /PRNewswire/ -- InvestorsObserverissues...
PR Newswire
4 months ago
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$34.16
$-1.87
(-5.19%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00